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Abstract
It is known that total telomere length is shorter in
invasive breast cancer than in normal breast tissue but
the status of individual telomere lengths has not been
studied. Part of the difficulty is that usually telomere
length in interphase cells is measured on all chromo-
somes together. In this study we compared normal
breast epithelium, duct carcinoma in situ (DCIS), and
invasive duct carcinoma (IDC) from 18 patients. Telo-
mere length was specifically measured on chromo-
some 17q and was found to be shorter in DCIS and
IDC than in normal breast epithelial cells, with more
heterogeneity in telomere length in DCIS associated
with IDC than in DCIS alone. More importantly, we
found that the shortening of telomere on chromosome
17q is greater than the average shortening of all telo-
meres. This finding indicates that telomere shortening
is not simply the result of the end replication problem;
otherwise, all telomeres should be subjected to the
same rate of telomere shortening. It seems there
are mechanisms that preferentially erode some telo-
meres more than others or preferentially protect some
chromosome ends. Our results suggest that the in-
creased level of telomere shortening on 17q may be
involved in chromosome instability and the progres-
sion of DCIS.
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Introduction
Breast cancer is one of the most common cancers afflicting
North American women. Although the majority of early-stage
breast cancers are not life threatening, a small proportion of
cases will progress to metastatic breast cancer. Invasive duct
carcinoma (IDC) is frequently observed to extend directly
from ducts containing duct carcinoma in situ (DCIS). How-
ever, not all cases of DCIS develop into invasive tumors.
Molecular markers hold the promise of becoming clinically
useful diagnostic tools, particularly markers that can be
studied in formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples, as virtually all DCIS is processed in this way for rou-
tine pathologic diagnosis. Because telomeres are involved in
maintenance of chromosomal stability, they represent one group
of markers of particular interest.
The telomere is a specialized structure at the end of
chromosomes consisting of a highly conserved repetitive
DNA sequence, (TTAGGG)n [1]. Telomeres form caps on the
ends of chromosomes that prevent fusion of chromosomal
ends and provide genomic stability. In normal somatic cells,
telomeres are progressively shortened with every cell division.
This shortening in normal human cells limits the number of cell
divisions. For human cells to proliferate beyond the senes-
cence checkpoint, they need to stabilize telomere length. This
is accomplished mainly by reactivation of telomerase [2].
Telomerase expression is under the control of many factors
[3–10]. Expression of telomerase can lead to cell immortaliza-
tion and is activated during tumorigenesis [11].
Using various approaches, it has been shown that telomere
length in DCIS is generally shorter than in normal breast
epithelial cells with inconsistent results with respect to asso-
ciations between tumor telomere length and clinicopathologic
features [12–15]. However, in other cancer types a correlation
between longer telomeres and more aggressive behavior of
cancer cells has been found [16,17]. Although these groups
have measured the average length of pantelomeres in their
studies, it has been reported that it may not be the average but
rather the shortest telomeres that constitute telomere dysfunc-
tion and limit cellular survival in the absence of telomerase [18].
It has been suggested that loss of telomere function occurs
preferentially on chromosomes with critically short telomeres
[18]. Martens et al. [19] found that chromosome 17p has the
shortest telomere among human chromosomes. However,
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Perner et al. [20] showed that chromomose 17p telomere is
among the shorter ones (but not the shortest), and its erosion
occurs at the same rate as all others. Interestingly, using BJ
fibroblast cells, Zou et al. identified chromosome 17q, not
chromosome 17p, as one of the 10 shortest telomeres with a
high frequency of signal-free ends [21].
Numerous studies have demonstrated genetic abnor-
malities on chromosome 17 in DCIS with rates approaching
60% to 80% [22,23], suggesting that oncogenes and tumor
suppressor genes in these regions may be particularly impor-
tant in the development of DCIS. A frequently amplified gene in
IDCandDCIS is thehumanepidermal growth factor receptor-2
(HER2) oncogene located on chromosome 17q. HER2 is a
member of a family of transmembrane receptor tyrosine
kinases with no identified ligand. HER2 is overexpressed
and amplified in 20% to 30% of IDC and up to 80% of DCIS.
Many groups have reported a correlation between HER2
amplification and poor prognosis [24,25]. Despite much inter-
est, the mechanism of HER2 amplification/overexpression
in many cases is unclear. We hypothesized that telomere
erosion on 17q could lead to instability on 17q and this may
be associated with HER2 amplification/overexpression.
In this study, we developed a technique to allow mea-
surement of specific telomeres in routinely processed clinical
samples. This allowed us to measure telomere length spe-
cifically on chromosome 17q in FFPE samples. We also
investigated the relationship between HER2 expression and
telomere shortening on chromosome 17q.
Materials and Methods
Sample Collection
Breast tissue was obtained from archival FFPE blocks
that were stored in the Pathology Department of University
Health Network and had been obtained initially for diagnosis.
Institutional research ethics board approval was obtained
for the study.
Quantitative Fluorescence In Situ Hybridization
To measure the relative changes in telomere length on
chromosome 17q in breast epithelium, quantitative fluores-
cence in situ hybridization (Q-FISH) was used. Metaphase
slides prepared from normal peripheral blood lymphocytes
(Vysis Inc., Downers Grove, IL) and the breast cancer cell
line MCF-7, colon cancer cell line HT-29, and prostate
cancer cell line Du-145 were used to optimize Q-FISH
conditions for two different probes the first, a PNA
(CCCTAA)3 pantelomere probe–fluorescein isothiocyanate
(FITC; Applied Biosystems, Bedford, MA). Because the
(CCCTAA)3 PNA probe is not able to distinguish the parental
telomeres from each other, all the telomere signals are the
average of two homologous chromosomes in our report.
We also used a specific subtelomeric DNA probe for
chromosome 17q (TelVysion 17q SpectrumOrange; Vysis)
as a guide to locate chromosome 17q telomeres. Using
these two probes, we were able to detect strong signals from
telomeres and the chromosome 17q subtelomeric region
simultaneously. The signals from these two probes were
close enough to allow direct analysis of telomere length on
the end of chromosome 17q in FFPE tissue samples.
Five-micrometer-thick FFPE tissue samples on positively
charged glass slides were deparaffinized with xylene,
washed with 100% ethanol, and air-dried followed by RNase
A treatment. Slides were then placed in 1 mol/l NaSCN at
80jC and washed in water at room temperature. After pepsin
digestion, slides were thoroughly washed with water followed
by dehydration in serial ethanol dilutions (70%, 90%, and
100%) at room temperature and air-dried. The sections and
the PNA pantelomere probe were then co-denatured at
80jC for 5 minutes in a Hybrite programmable heating block
(Vysis) followed by incubation in a dark humidified chamber
for 90 minutes at 25jC. Then slides were hybridized with a
denatured specific chromosome 17q probe mixture and incu-
bated overnight at 33jC. Slides were washed in 2  SSC/
0.3% NP-40 at 73jC, 2  SSC/0.3% NP-40 and 2  SSC at
room temperature followed by dehydration in serial ethanol
dilutions and air-dried. Finally, the slides were counterstained
with 4V,6 diamidino-2-phenylindole (DAPI, Vector Laborato-
ries, Inc., Burlingame, CA) and viewed with a fluorescence
microscope (Leica DMRA2, Wetzlar, Germany).
Image Capturing and Analyzing
The normal breast epithelium, DCIS, and invasive areas
in each tissue section were identified by hematoxylin and
eosin staining (Figure 1A). Then, parallel sections were
studied for the Q-FISH analysis (Figure 1B–D). In this study,
we measured the length of telomere in normal breast epi-
thelium (n = 8), DCIS (n = 14), and IDC (n = 12) from 18
patients. For each type of tissue (normal breast epithelium,
DCIS, and IDC) a minimum of 20 nuclei in five different areas
were scored for the following variables: the total telomere
length (expressed as intensity), the telomere length at the
end of chromosome 17q (expressed as intensity), and sub-
telomeric chromosome 17q (expressed as intensity).
The TelVysion 17q SpectrumOrange probe contains a
locus within 300 kb of the end of the chromosome (Vysis).
This corresponds to a physical distance within 0.7 mm from
chromosome 17q subtelomeric signals [26]. We searched for
the telomere signals within 0.7-mm distance from the chro-
mosome 17q signals. To ensure that we were not counting
overlapping ends of other chromosomes we captured a
series of Z stacked images at 0.7-mm intervals.
Images were captured using Openlab 4.0.3d8 software
(Improvision, Viscount Centre II, University of Warwick Sci-
ence Park, Coventry, England, UK; http://www.improvision.
com). Finally the images were analyzed with Image J soft-
ware (developed at the Research Services Branch of the
National Institute of Mental Health, National Institutes of
Health; http://rsb.info.nih.gov/nih-image).
Immunohistochemical Staining of Paraffin Sections
for HER2
Adjacent FFPE tissue sections from the same blocks were
dewaxed in xylene and blocked for endogenous peroxidase
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in 3% hydrogen peroxide for 10 minutes. After microwave
antigen retrieval, the sections were blocked for endogenous
biotin with the biotin blocking kit (Vector Laboratories). The
sections were incubated with 1:300 diluted primary anti-
body HER2 rabbit polyclonal antibody (Dako, Carpinteria,
CA) for 1 hour at room temperature and rinsed in PBS
followed by incubation with biotin-conjugated anti– rabbit
IgG (Signet Laboratories, Inc., Dedham, MA) for 30 minutes.
After incubation with streptavidin-labeled HRP for 30 minutes
(Signet kit) and rinsing in PBS, the sections were incubated
in NovaRed substrate (Vector Laboratories) for another
5 minutes. Finally the nuclei were counterstained in Mayer’s
hematoxylin for 10 seconds and the sections were dehy-
drated, cleared, and premounted for microscopic evaluation.
Samples having more than 10% of cells with complete cell
membrane staining of moderate to strong intensity were con-
sidered as HER2 positive.
Data Analysis
In this study, the following variables were used in the analy-
sis: telomere length (TelGen) = average of the telomere length
intensity (per patient, per type of tissue, over the minimum
Figure 1. FISH analysis of breast FFPE sections. (A) Comparable hematoxylin and eosin sections were used to determine regions of interest. (B–D) FISH with
subtelomeric DNA probe to label chromosome 17q (orange signals) and pantelomereic PNA probe (green signals) on FFPE sections (original magnification, 100).
Representative images of normal breast epithelial tissue, DCIS, and IDC are shown in each row. DAPI was used as a counterstain. Identical images in black and
white shown in (C–D) with nuclei outlined in gray and (C) telomere and (D) subtelomereic chromosome 17q signals represented by the dark spots (indicated by
arrows). Note reduction in telomere signal number, intensity, and size in DCIS and IDC compared with normal tissue.
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20 nuclei); normalized telomere length (N-TelGen) = average
telomere length divided by the average chromosome 17q
intensity; chromosome 17q telomere length (TelCh17q) =
average of the telomere length intensity of the chromosome
17q PNA probe–FITC; normalized chromosome 17q telo-
mere length (N-TelCh17q) = chromosome 17q telomere length
divided by the average chromosome 17q intensity; and
immunohistochemical percentage positivity for HER2 over-
expression. The intensity of the subtelomeric chromosome
17q signals was used to normalize the values for telomere
length. Cells without 17q signals were not scored.
Statistical Analysis
The exact Wilcoxon signed rank test and the exact
Wilcoxon rank sum test were used to compare the telomere
lengths between normal breast epithelium, DCIS, and IDC
samples. Both tests are nonparametric. They are useful
when the sample size is small or the assumption of normality
does not hold.
Results
In this study, the variables (N-TelGen and N-TelCh17q) were
compared between normal, DCIS, and IDC tissues. Using
the exact Wilcoxon signed rank test, we found that total telo-
mere length in DCIS was significantly shorter than that mea-
sured in normal breast epithelium (P = .023) (Figure 2A).
Likewise, the telomere length on chromosome 17q was
notably shorter than its counterpart in DCIS compared
with normal tissues (P = .078) (Figure 2B). In contrast,
the differences in the length of total telomere and telomere
on chromosome 17q were minimal between DCIS versus
IDC (Figure 2, A and B). Upon investigating the variables,
N-TelGen and N-TelCh17q, among DCIS alone (n = 6) and
DCIS + IDC (n = 8), no significant changes were apparent
between these two groups (Figure 3, A and B).
To study if the telomere shortening for chromosome 17q
and total telomeres occurs at the same rate, we com-
pared the telomere shortening of chromosome 17q in DCIS
and normal tissue with total telomere shortening in the
same tissues. For this purpose, we first calculated the fold
Figure 2. Comparison of the normalized intensities of telomere length between normal breast epithelial tissue, DCIS, and IDC: (A) normalized total telomere
length, (B) normalized chromosome 17q telomere length. Note significant reduction in telomere intensity in DCIS and IDC in comparison with normal breast
epithelial tissue.
Figure 3. Distribution of telomere length between DCIS and DCIS associated with IDC: (A) normalized total telomere lengths, (B) normalized chromosome 17q
telomere lengths. There are no significant differences in telomere length between DCIS and DCIS associated with IDC.
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decrease of the N-TelCh17q compared with N-TelGen for
both DCIS and normal tissue in each sample. Then we de-
fined the telomere shortening as the fold decreases in DCIS
compared with normal tissue for both chromosome 17q and
for total telomeres in each sample. We found that the median
telomere length on chromosome 17q in DCIS decreased
by 89.8% compared with normal tissue, whereas the me-
dian of telomere length on all the rest of the chromosomes
decreased by 49% (Table 1).
To study the relationship between telomere shortening on
chromosome 17q and HER2 expression, we compared the
intensities for TelGen, N-TelGen, TelCh17q, and N-TelCh17q
between HER2-negative samples (n = 18) and HER2-
positive samples (n = 16). Using the exact Wilcoxon rank
sum test, we found that total telomere length in the HER2-
positive group is not significantly different from telomere
length in the HER2-negative group (Table 2). Likewise, no
significant differences were found between the telomere
length on chromosome 17q in both HER2 positive and
negative (Table 2), indicating that the expression of HER2
is independent from telomere shortening for both total chro-
mosomes and chromosome 17q.
Discussion
Invasive breast cancer is frequently observed to extend
directly from ducts containing DCIS; however, not all cases
of DCIS develop into invasive tumors. The challenge is to
identify molecular markers that will allow prediction of which
cases of DCIS will progress to IDC. Telomere length is
reduced in IDC. Hence, we chose to investigate telomere
length as a potential marker.
It has been reported that it may not be the average
telomere length but rather the shortest telomeres that con-
stitute telomere dysfunction as loss of telomere function has
been shown to occur preferentially on chromosomes with
critically short telomeres [18]. However, although the p arm
of chromosome 17 (chr17p) has been reported to be the
shortest telomere [19], it is the q arm of chromosome 17
(chr17q), not chromosome 17p, that shows a signal-free end
with high frequency in senescent cells [21]. This means
that telomere shortening does not occur at the same rate
for all telomeres; otherwise, chromosome 17p should be one
of the signal-free end chromosomes. In agreement with
these findings, our data show that telomere shortening on
chromosome 17q is significantly greater than the average
erosion of total telomeres in DCIS compared to normal
breast epithelium, supporting the idea that the erosion of
telomeres can be different for different chromosomes.
Although we observed this event in malignant cells, other
groups have shown similar results in different cell types
[19,21]. Using BJ fibroblasts, Zou et al. [21] found that
there were no signal-free ends in young BJ cells, whereas
in near-senescent BJ cells chromosome 17q exhibited one
of the highest frequencies of signal-free ends. Their report
showed that chromosome 17p has no signal-free ends (0%),
although this arm of chromosome 17 has been reported to
have the shortest telomere among human chromosomes.
Similarly, Martens et al. [19] showed that out of 13 sam-
ples from 10 different donors, 3 of them had significantly
short chromosome 17q telomere lengths compared to the
median for each individual donor (Figure 4 in Ref. [19]).
All these three samples were from hematopoietic bone
marrow cells, which have a high proliferation capacity. Thus,
it appears that cells with higher proliferation rates show
greater telomere shortening on chromosome 17q compared
with chromosome 17p and the average of total telomeres.
Based on these observations, we speculate that telomere
shortening is not simply the result of the end replication
problem. These data indicate that there are mechanisms
that preferentially erode some telomeres more than others
or preferentially protect some chromosome ends. Based on
these findings, we suggest that telomere length on chromo-
some 17q plays a role in the progression of DCIS, possibly
through chromosome instability. However, further studies
are required to validate the mechanism behind the differen-
tial telomere shortening for different chromosomes as well
as the role of this mechanism in chromosome instability
and cancer.
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Table 1. Comparing Telomere Shortening of Chr17q in DCIS and Normal
Tissue with Total Telomere Shortening in the Same Tissues.
Samples Group A Group B
1 82.517 59.4769
2 100.000 71.4190
3 97.081 77.3483
4 90.364 38.5657
5 89.248 64.1070
6 88.889 38.6999
7 72.074 47.4690
8 100.000 39.3684
Median 89.8063 49.4227
SD 9.4823 39.5324
The telomere shortening in DCIS compared with normal breast epithelium
for both chr17q (Group A) and for total telomeres (Group B). Group A: fold
decrease of N-TelCh17q in DCIS compared with normal tissue. Group B: fold
decrease of N-TelGen in DCIS compared with normal tissue.
Table 2. Association between Telomere Length and HER2 Expression.
HER2 Negative
(n = 18), Median
HER2 Positive
(n = 16), Median
P (Wilcoxon
Sum Rank)
Total telomere lengths
(normalized)
0.34 0.45 0.82
Telomere length on
chromosome 17q
(normalized)
0.058 0.029 0.19
Wilcoxon rank sum test was used to compare the intensities for the total
telomere lengths and telomere length on Ch17q between HER2-negative
samples (n = 18) and HER2-positive samples (n = 16).
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